We are leading a revolution in oncology to redefine cancer care
We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We think differently about the underlying genetic causes of cancer. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.
Medicines: Portfolio and Pipeline
With our portfolio, our pipeline and our people, we aim to revolutionise cancer care. We follow the science, wherever it takes us, in pursuit of the best medicines. Through this relentless quest for innovation, we have created one of the most diverse portfolios and pipelines in the industry – encompassing molecules and modalities designed to preferentially kill cancer cells, at every stage of disease.
Key disease areas
Our focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, we hope to achieve life-changing benefits for patients.
Our scientific platforms
Our advances across our six scientific platforms have helped to improve patient outcomes. Further developments in epigenetics and across cell, gene and combination therapy hold the promise of new possibilities.
Our Oncology medicines
Our medicines are approved in individual countries for specific uses, and the information we provide for patients is governed by local regulations. In some countries, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. However, please note that in some countries we are not permitted to provide very much, or sometimes any, information on our prescription medicines, so you should only obtain information from trustworthy sources, and always ask a healthcare professional for advice about medicines.
goserelin acetate implant
Our Oncology pipeline
Our industry-leading pipeline includes investigational therapies in various stages of clinical development – from approved medicines to earlier-stage molecules in clinical trials.
Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III or have been submitted for regulatory approval and may include assets that are launched in one or more major markets (removed when launched in all applicable major markets).
Oncology (as of 11 February 2021)
Collaboration in Oncology
Despite huge advances in cancer care over recent decades, we know there is still more to be achieved. We cannot do this alone; we know that outsmarting cancer requires a collective and collaborative approach. From drug discovery collaborations to commercial partnerships, we are sourcing new medicines, investing in the brightest minds and funding research across the globe, with a focus on maximising impact through shared knowledge and experience.
Patients are at the heart of everything we do. Through relentless innovation and a commitment to scientific discovery we are catalysing changes in the practice of medicine to transform the patient experience. By working with the community, we can empower patients and caregivers, and are able to evolve the way cancer is treated by accelerating the uptake of the latest advancements.
Through collaborations with researchers, academia, healthcare providers, governments, industry and scientific organisations, patients and their families, we are uncovering unique insights on how we can establish new standards of screening, diagnostics and treatment.
In the spotlight
We have partnered with leading solution providers, scientific societies and clinical experts to create HAYA (pronounced hah-yah) – a fully-integrated cancer care management platform for patients, healthcare providers and care centres.
HAYA addresses the need for simplification of the oncology patient pathway by enabling continuity of care and connectivity between healthcare professionals and patients.
This unique platform combines telemonitoring, teleconsultation, home care services, treatment navigation, personalised support, tracking, motivation and education – all through a single interface. HAYA provides a holistic and personalised view of care plans from diagnosis to treatment to follow up.
New Normal, Same Cancer
To address the impact of the COVID-19 pandemic on cancer care worldwide, AstraZeneca has partnered with global patient coalitions representing millions of patients from around the world to launch New Normal, Same Cancer. This program raises awareness of the impact of COVID-19 and calls for patients to contact their doctor and return to cancer care services, including anyone who has paused treatment, missed routine checks or is experiencing symptoms that may be due to cancer.
Lung Ambition Alliance
Lung cancer is at the forefront of AstraZeneca’s research and development focus. Our expanding portfolio aims to provide medicines that can improve outcomes at every stage of the disease. But we know if we are to make meaningful progress for lung cancer patients, we cannot work alone. We have partnered with the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), and Guardant Health to form the Lung Ambition Alliance. Together we are taking urgent action to double five-year survival in lung cancer globally by 2025 – prioritising research and projects that increase screening, deliver innovative medicine and improve quality care.
Our People & Culture
Making significant scientific and cancer care advancements requires courage, curiosity, collaboration, and a passion for learning which is why we encourage disruptive thinking where failure is an opportunity to learn. Our team shares a united vision and everything we do begins with the science and centres around patients. Our people are driven by our bold ambition and together we can grow and achieve excellence.
Our team doesn’t fit one mould and we foster an inclusive culture where diversity drives innovation and progress, by challenging assumptions and creating opportunities for new discoveries and creative solutions.
Meet our team
Be among colleagues who are driven by our passion, our people and a culture of innovation. We value courage, curiosity, collaboration, and a passion for learning. We encourage disruptive thinking where failure is an opportunity to learn – having the freedom to take risks without fear of failure.
IDMC has concluded that OlympiA trial of Lynparza crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis
Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer
Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer
Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Veeva ID: Z4-30595
Date of Prep: 3 February 2021